These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661 [TBL] [Abstract][Full Text] [Related]
4. Determinants of overall survival in patients with metastatic uveal melanoma. Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of cutaneous and uveal melanoma liver metastases. Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254 [TBL] [Abstract][Full Text] [Related]
6. Integrating Single-cell and Bulk RNA-seq to Construct a Metastasis-related Model for Evaluating Immunotherapy and Chemotherapy in Uveal Melanoma. Du Y; Jiang X; Zhang Y; Ying J; Yi Q Curr Med Chem; 2024; 31(42):7030-7042. PubMed ID: 38173196 [TBL] [Abstract][Full Text] [Related]
7. The Role of Immune Checkpoint Blockade in Uveal Melanoma. Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269 [TBL] [Abstract][Full Text] [Related]
8. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma. Jindal V Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567 [TBL] [Abstract][Full Text] [Related]
9. Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach. Botticelli A; Cirillo A; Pomati G; Cortesi E; Rossi E; Schinzari G; Tortora G; Tomao S; Fiscon G; Farina L; Scagnoli S; Pisegna S; Ciurluini F; Chiavassa A; Amirhassankhani S; Ceccarelli F; Conti F; Di Filippo A; Zizzari IG; Napoletano C; Rughetti A; Nuti M; Mezi S; Marchetti P Cancer Immunol Immunother; 2023 Jul; 72(7):2217-2231. PubMed ID: 36869232 [TBL] [Abstract][Full Text] [Related]
10. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis. Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026 [TBL] [Abstract][Full Text] [Related]
11. Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma. Stålhammar G; Seregard S; Grossniklaus HE Cancer Med; 2019 Jun; 8(6):2784-2792. PubMed ID: 30993893 [TBL] [Abstract][Full Text] [Related]
12. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. Bol KF; Ellebaek E; Hoejberg L; Bagger MM; Larsen MS; Klausen TW; Køhler UH; Schmidt H; Bastholt L; Kiilgaard JF; Donia M; Svane IM Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623302 [TBL] [Abstract][Full Text] [Related]
13. The Current State of Systemic Therapy of Metastatic Uveal Melanoma. Koch EAT; Heppt MV; Berking C Am J Clin Dermatol; 2024 Sep; 25(5):691-700. PubMed ID: 38907174 [TBL] [Abstract][Full Text] [Related]
14. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients. Wang Q; Zhang J; Tu H; Liang D; Chang DW; Ye Y; Wu X J Immunother Cancer; 2019 Nov; 7(1):334. PubMed ID: 31783776 [TBL] [Abstract][Full Text] [Related]
15. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Qin Y; Petaccia de Macedo M; Reuben A; Forget MA; Haymaker C; Bernatchez C; Spencer CN; Gopalakrishnan V; Reddy S; Cooper ZA; Fulbright OJ; Ramachandran R; Wahl A; Flores E; Thorsen ST; Tavera RJ; Conrad C; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Amaria RN; Hwu P; Wargo JA; Lazar AJ; Patel SP Oncoimmunology; 2017; 6(6):e1321187. PubMed ID: 28680759 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives. Kaštelan S; Antunica AG; Oresković LB; Pelčić G; Kasun E; Hat K Curr Med Chem; 2020; 27(8):1350-1366. PubMed ID: 31272342 [TBL] [Abstract][Full Text] [Related]
17. Radiotherapy may augment response to immunotherapy in metastatic uveal melanoma patients. Grynberg S; Stoff R; Asher N; Shapira-Frommer R; Schachter J; Haisraely O; Lawrence Y; Ben-Betzalel G Ther Adv Med Oncol; 2022; 14():17588359221131521. PubMed ID: 36339927 [TBL] [Abstract][Full Text] [Related]
18. Differential modulation and prognostic values of immune-escape genes in uveal melanoma. Basile MS; Mazzon E; Russo A; Mammana S; Longo A; Bonfiglio V; Fallico M; Caltabiano R; Fagone P; Nicoletti F; Avitabile T; Reibaldi M PLoS One; 2019; 14(1):e0210276. PubMed ID: 30653520 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment. Masaoutis C; Kokkali S; Theocharis S Expert Opin Investig Drugs; 2021 May; 30(5):555-569. PubMed ID: 33650931 [TBL] [Abstract][Full Text] [Related]
20. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma. Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]